Streptococcus pneumoniae type 4 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 4 of Streptococcus pneumoniae. It is an active immunization... It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
- First approval
- Canada, 2005 · United States, 1983 · European Union, 2021
- Also known as
- pneumococcal capsular polysaccharide type 4 vaccine · Pneumococcal polysaccharide serotype 4
- Brand names
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 4 capsular polysaccharide antigen, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account